Strongbridge Biopharma plc Overview
Strongbridge Biopharma plc (SBBP) has a ROE of -90.47%, below the Healthcare sector average of 22.01%.
Get informed when a big investor buys or sells
+ Follow-90.47%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Strongbridge Biopharma plc (SBBP) currently reports a ROE of -90.47%. That is below the Healthcare sector average of 22.01%. Use the charts on this page to explore Strongbridge Biopharma plc's ROE history and peer comparisons.
Strongbridge Biopharma plc's ROE of -90.47% is lower than the Healthcare sector average of 22.01%. That is roughly 511.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Strongbridge Biopharma plc's current -90.47% should be judged against Healthcare norms (sector average: 22.01%) and against SBBP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -90.47%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Strongbridge Biopharma plc, and consider following SBBP for alerts when major investors trade the stock.
Strongbridge Biopharma plc is classified in the Healthcare sector. On ROE, it currently shows -90.47% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SBBP with unrelated industries.
